Author

Mary Lazell-Wright

University of Saskatchewan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Approach:experimental assay· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Assay:bulk RNA-seq· 1 Assay:ChIP-seq· 1 Research Focus:chromatin & epigenetic regulation· 1 Assay:CRISPR screen· 1

Frequent Co-Authors

Anand KrishnaniD· 4 shared Andrew FreywaldiD· 4 shared Frederick S. VizeacoumariD· 4 shared Jared D. W. PriceiD· 4 shared Vincent MarandaiD· 4 shared Alain Morejon Morales· 3 shared Ashtalakshmi Ganapathysamy· 3 shared Franco J. VizeacoumariD· 3 shared

Activity by Year

2025-2025 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

Anand KrishnanORCID

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Organoid Pharmacotyping of Pancreatic Cancer Enables Functional Precision Oncology and Drug Repurposing

He Dong, Frederick S. Vizeacoumar, Yue Zhang, Nicholas Jette, Jared D. W. Price, Vincent Maranda, Lihui Gong, Tanya Freywald, Jeff Patrick Vizeacoumar, Mary Lazell-Wright, Saruul Uuganbayar, Jaylynn Quail, Alain Morejon Morales, Ayaan Rizvi, Rani Kanthan, , Franco J. Vizeacoumar

This paper uses patient-derived pancreatic cancer organoids to identify drug sensitivities linked to tumor differentiation and pathway mutations, revealing new therapeutic targets in chemoresistant tumors.

bioRxiv · Dec 3, 2025 · PreprintCancer Biology

Identification of targetable vulnerabilities of PLK1-overexpressing cancers by synthetic dosage lethality

Chelsea E. Cunningham, Frederick S. Vizeacoumar, Yue Zhang, Liliia Kyrylenko, Simon Both, Vincent Maranda, He Dong, Jared D. W. Price, Peng Gao, Konrad Wagner, Yingwen Wu, Mary Lazell-Wright, Ashtalakshmi Ganapathysamy, Rithik Hari, Kalpana Kalyanasundaram Bhanumathy, , Franco J. Vizeacoumar

The paper identifies synthetic dosage lethality targets for PLK1-overexpressing cancers using genome-wide screens and validates key hits to show their therapeutic potential.

Cell Genomics · May 9, 2025Peer-reviewedCancer Biology

A novel role for Neurog2 in MYCN driven neuroendocrine plasticity of prostate cancer

Prachi Walke, Jared D. W. Price, Frederick S. Vizeacoumar, Nickson Joseph, Vincent Maranda, Bari Chowdhury, Jay Patel, Yue Zhang, He Dong, Lara New, Ashtalakshmi Ganapathysamy, Li Hui Gong, Mary Lazell-Wright, Hussain Elhasasna, Kalpana Kalyanasundaram Bhanumathy, , Franco J. Vizeacoumar

This study identifies Neurog2 as a potential therapeutic target for MYCN-driven neuroendocrine prostate cancer by showing its role in promoting tumor growth and NEPC development.

Oncogene · Apr 29, 2025Peer-reviewedCancer Biology

Epigenetic Control of TERRA by FTSJ3 is Critical for Telomerase-Driven Cancers

Jared D. W. Price, Frederick S. Vizeacoumar, Omar Abuhussein, Vincent Maranda, Yue Zhang, Hironori Adachi, Liliia Kyrylenko, Aline Rangel Pozzo, He Dong, Li Hui Gong, Prachi Walke, Ashtalakshmi Ganapathysamy, Connor Denomy, Tanya Freywald, Renuka Dahiya, , Franco J. Vizeacoumar

The paper identifies FTSJ3 as a critical vulnerability in hTERT-overexpressing cancers by showing its role in TERRA methylation and telomeric heterochromatin stability.

bioRxiv · Jan 26, 2025 · PreprintCancer Biology